On September 24, 2026, TOUYUN BIOTECH (01332) announced that it granted share options under its share option scheme to one director and 22 employees, allowing them to subscribe for a total of 74.5838 million ordinary shares of the company with a par value of HK$0.04 each, subject to acceptance by the grantees.
The grant was made pursuant to the company's share option plan, and the options remain subject to acceptance by the respective grantees before they become effective.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.